Mylan has launched a generic version of Roche’s Bonviva tablets for the treatment of osteoporosis.

The Ibandronic Acid Film Coated Tablets have been released on the day the patent for Bonviva expired.

Didier Barret, Mylan EMEA President, said the manufacturer is “excited” to add the tablets to its portfolio of more than 350 products in the UK.

The treatment is used in postmenopausal women with osteoporosis who are at an increased risk of fracture.

The drug had sales of around £7.5 million in the UK for the year ending March 2012, according to IMS Health.

Mylan, the first company to launch a generic Ibandronic Acid formulation in the UK, recently launched the product in Spain after Bonviva’s protection expired there.

Share this article: